Sickle-cell thalassemia, unspecified, with crisis with other specified complication
ICD-10 D57.418 is a billable code used to indicate a diagnosis of sickle-cell thalassemia, unspecified, with crisis with other specified complication.
Sickle-cell thalassemia is a genetic blood disorder characterized by the presence of both sickle cell disease and thalassemia, leading to abnormal hemoglobin production. Patients with this condition experience episodes of pain known as sickle cell crises, which occur when sickle-shaped red blood cells obstruct blood flow in small vessels. The unspecified nature of this code indicates that the specific type of thalassemia is not detailed, which can complicate treatment and management. Complications may include hemolytic anemia, where red blood cells are destroyed faster than they can be produced, leading to fatigue, pallor, and jaundice. Other complications can arise from organ damage due to chronic hypoxia and vaso-occlusive events. Genetic factors play a crucial role, as both sickle cell disease and thalassemia are inherited conditions, necessitating thorough family history documentation. Management often involves pain control, hydration, and blood transfusions, and may require coordination with hematology specialists for comprehensive care.
Detailed lab results, genetic testing, and treatment plans must be documented.
Management of sickle cell crises, blood transfusion therapy, and monitoring for complications.
Ensure accurate documentation of hemoglobin levels and crisis frequency for appropriate coding.
Family history and genetic testing results should be included.
Counseling for patients and families regarding genetic risks and implications.
Documentation of genetic counseling sessions is crucial for coding.
Used during hospitalization for severe anemia due to sickle-cell thalassemia crisis.
Document the indication for transfusion and patient response.
Hematology specialists should ensure accurate coding based on the patient's condition.
Sickle-cell thalassemia is a combination of sickle cell disease and thalassemia, leading to unique clinical presentations and management challenges, whereas sickle cell disease primarily refers to the presence of sickle-shaped red blood cells without the thalassemia component.
